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(92.4%), whereas CCA represented merely 7.6% (42 cases) of 
the overall series. Hepatitis B virus (HBV; 44.3%) and hepati-
tis C virus (HCV; 43%) infection rates were similar among the 
HCC patients, while small subsets of CCA patients were in-
fected with HBV (15.4%) or HCV (11.5%). Most HCC (84%) 
and CCA (73.8%) patients received palliative treatment only. 
 Conclusion: The present study indicates that HCC is the 
main form of primary hepatic neoplasm among PLC pa-
tients attending a hospital in Cambodia. HBV and HCV infec-
tions represented equivalent burdens and major contribut-
ing factors to HCC. Therefore, the implementation of pre-
vention programs for these infectious agents should 
become a priority for health policy makers in the country. 
 © 2016 S. Karger AG, Basel 
 Key Words 
 Hepatocellular carcinoma · Cholangiocarcinoma · 
Hepatitis B virus · Hepatitis C virus ·  Opisthorchis viverrini · 
Cambodia 
 Abstract 
 Objectives: Hepatocellular carcinoma (HCC) is the main 
type of primary liver cancer (PLC) worldwide, but cholangio-
carcinoma (CCA) may be predominant in some specific re-
gions of Southeast Asia. The aim of the present study was to 
delineate a pattern of Cambodian PLC patients attending 
the Calmette Hospital in the Cambodian capital Phnom 
Penh.  Materials and Methods: A total of 553 medical charts 
diagnosing PLCs from January 2003 to May 2015 were ob-
tained from both the Oncology and Hepato-Gastroenterol-
ogy Departments of the Calmette Hospital.  Results: HCC 
was the predominant type of PLC recorded, with 511 cases 
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 The work was conducted in the Calmette Hospital, Phnom Penh, 
Cambodia. 
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 Introduction 
 Primary liver cancer (PLC) is associated with a high 
mortality rate; it is the second cause of cancer-related 
death worldwide  [1] . Along with Sub-Saharan Africa, 
Eastern and Southeastern Asia represents a major region 
of incidence of the disease, ranking respectively first and 
second, both in terms of incidence and mortality  [2] . In 
Cambodia, very little data about the cancer burden is cur-
rently available. According to the estimates available, 20% 
of all male cancers in the country are PLCs, making it the 
most frequent tumor in Cambodian men  [3, 4] .
 Hepatocellular carcinoma (HCC) and cholangiocarci-
noma (CCA) are the two main histologic types of PLC  [5] . 
HCC is globally known as the leading form of liver cancer 
and accounts for up to 85% of incidences worldwide  [6] . 
However, CCA represents the predominant form of PLC 
in some specific regions of Southeast Asia. For instance, 
CCA is responsible for 90% of the liver cancer cases mon-
itored in the Khon Kaen province of Thailand  [7–9] .
 Hepatitis B virus (HBV) and hepatitis C virus (HCV) 
are considered to be the main etiological factors for HCC. 
These two infectious agents are estimated to be respon-
sible for more than three quarters (78%) of the HCC cas-
es worldwide  [10] . In Southeast Asia, which is a highly 
endemic area for HBV, the major risk factor for HCC is 
chronic HBV infection  [2, 11] . So far, the number of cas-
es of HCC related to HCV infection in the region was 
poorly known and considered to be of marginal signifi-
cance when compared with that linked to HBV  [10] . Con-
cerning the risk factor for CCA, it results largely from the 
infection with the liver fluke  Opisthorchis viverrini en-
demic to Cambodia, Laos, Thailand, and Vietnam  [8, 9, 
12] . According to the International Agency for Research 
on Cancer (IARC), 6 million people are infected with  O. 
viverrini in Thailand, 2 million in Laos, and 600,000 in 
Cambodia  [13] . 
 In Cambodia, hepatitis B surface antigen (HBsAg) se-
roprevalence in the general population is estimated at be-
tween 7.7 and 13%, whereas the hepatitis C antibody se-
roprevalence range is between 2.3 and 14.7%  [4, 14–18] . 
Concerning the liver fluke, a high parasitic prevalence has 
been recorded in some provinces, especially in Kampong 
Cham, Kampong Thom, Kandal, Kratie, and Takeo prov-
inces. In these regions, infestation rates among the gen-
eral population range from 1.3 to 65.1%  [19–22] . 
 With the exception of a single study that aimed to de-
scribe the clinical and demographic features of Cambo-
dian HCC patients at a single center  [4] , no data have 
been published on CCA and HCC tumor presentation in 
this country. Therefore, the present work was carried out 
with the objective of describing and comparing the clini-
co-epidemiological features of both CCA and HCC in 
Cambodian patients attending the Calmette Hospital 
(Phnom Penh, Cambodia) over a 13-year period.
 Materials and Methods 
 The Department of Oncology of the Calmette Hospital, was 
opened in 2012. Prior to 2012, the Department of Hepato-Gastro-
enterology was in charge of attending to the PLC patients. We thus 
carried out a retrospective study of the archives of these two de-
partments in order to collate the PLC medical charts that had been 
compiled over an almost 13-year period from January 2003 to May 
2015.
 A total of 553 medical charts of PLC patients were reviewed. 
The data provided on paper, such as medical reports, daily follow-
up sheets, laboratory and imaging results, were extracted from the 
patients’ files available in each department and recorded in Excel 
file version 2013 (Microsoft). Sociodemographic information, 
clinical manifestations, biological analyses, medical imaging, 
method of diagnosis, and treatment outcomes were also moni-
tored and compiled into the database. 
 However, due to poor resources in the country, none of the files 
examined included all items listed above. As a consequence, sero-
logical parameters, biochemistry analyses, diagnostic imaging, and 
therapeutic options were not always available (ranging from 60% for 
the γ-glutamyl transpeptidase level to 100% for clinical features).
 The diagnosis of HCC at the Calmette Hospital was based on 
clinical, biochemical, and imaging criteria. The three decisive fea-
tures were: (1) the presence of liver cirrhosis and signs of neoplas-
tic disease in an alcoholic patient or a patient chronically infected 
with HBV or HCV, (2) α-fetoprotein (AFP) >350 ng/ml, and (3) 
nodule size over 20 mm (by ultrasound examination). In other 
cases (AFP <350 ng/ml and/or nodule size ranging between 10 and 
20 mm), the diagnosis was made using computed tomography 
showing a typical arterial pattern. Regarding clinical symptoms, 
ascites, portal hypertension, jaundice, liver mass at palpation, hep-
atomegaly, liver collateral circulation, splenomegaly, hemorrhag-
es, bruises, encephalopathy, pain, and weight loss were the most 
frequent features found in patients. In the case of CCA patients, 
the diagnosis was predominantly made based on personal back-
ground (presence of primary sclerosing cholangitis), clinical fea-
tures (jaundice, pale stool, dark urine, and pruritus), biochemical 
parameters (elevation in total bilirubin, direct bilirubin, and ami-
notransferases) suggesting a biliary obstruction, the presence of 
tumor markers (elevation in CEA and CA 19-9, and normal AFP) 
as well as on ultrasound examination (biliary ductal dilatation and 
related mass lesion) and on the results of the CT scan (bile duct 
dilatation and tumor mass).
 Differential diagnosis between HCC and CCA was based on 
several criteria: personal background and risk factors (chronic 
HBV/HCV infection, alcohol consumption), clinical features (liv-
er cirrhosis, signs of portal hypertension, signs of biliary obstruc-
tion, ascites), laboratory parameters (transaminases, bilirubin, 
AFP, CEA, CA 19-9), and imaging techniques (location and size of 
the mass, enhancement pattern).
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 Imaging modalities included mostly ultrasonography testing 
for 94.3% HCC patients and 94.1% CCA patients, while only 15.2% 
HCC patients and 58.8% CCA patients had a computed tomogra-
phy scan. Neither liver biopsy nor magnetic resonance imaging 
was performed.
 Regarding the clinical chemistry, laboratory analyses were per-
formed in the Biochemistry Department of the Calmette Hospital, 
where the following parameters were determined: γ-glutamyl trans-
peptidase, alkaline phosphatase, aspartate and alanine aminotrans-
ferase, bilirubin, prothrombin time, hemoglobin, albumin, and 
AFP. It should be noted that, until 2014, the AFP level was indicated 
as ‘>350 ng/ml’ for each value above 350 ng/ml in the biological re-
port. Thus, no fully accurate data were available for this parameter. 
 Other information, which would have been useful for the study, 
including tumor grade, infection by  O. viverrini , aflatoxin con-
tamination, arsenic exposure, type of alcohol consumed, pack-year 
units for cigarette smoking, and associated disorders (except dia-
betes and hypertension), was not present in the medical records. 
Moreover, no precise information was given for the serological 
tests used in the diagnosis of HBV and HCV. 
 Different statistical analyses were performed according to the 
set of data analyzed. Data were recorded in Microsoft Excel 2013 
(Microsoft) and later analyzed using SPSS Statistic software ver-
sion 22.0 (IBM). Comparisons between groups (numerical data) 
or proportions (categorical data) were realized using the Student
t test or Mann-Whitney test, ANOVA and the Fisher exact test as 
appropriate. Results of the analysis were considered statistically 
significant if the probability of occurrence by chance was less than 
5%. The free and open-source QGIS software version 2.8.2 was 
used to elaborate repartition maps.
 The study was carried out in accordance with the ethical prin-
ciples of the Declaration of Helsinki and was approved by the Na-
tional Ethics Committee for Health Research under the guidance 
of the Ministry of Health of Cambodia in January 2015. 
 Results 
 Descriptive Characteristics of the 553 Patients  
 Out of the 553 patients included, 511 (92.4%) had a 
diagnosis of HCC and 42 (7.6%) were diagnosed with 
CCA. The demographic characteristics of HCC and CCA 
Patients characteristics HCC patients CCA patients
Overall subjects
Total number 511 (92.4%) 42 (7.6%)
Age (n = 511/42), years
Mean ± SD 58.1 ± 11.9 62.3 ± 11.9
Range 28 – 91 40 – 90
Sex (n = 511/42)
Male 369 21
Female 142 21
Sex ratio 2.6 1
Symptoms and signs (n = 511/42)
Abdominal pain 263 (51.4%) 25 (59.5%)
Ascites 340 (66.5%) 12 (28.6%)
Asthenia 132 (25.8%) 9 (21.4%)
Fever 69 (13.5%) 7 (16.7%)
Gastrointestinal bleeding 168 (32.9%) 1 (2.4%)
Hepatomegaly 226 (44.2%) 9 (21.4%)
Jaundice 131 (25.6%) 31 (73.8%)
Edema 37 (7.2%) ND
Pruritus 6 (1.2%) 11 (26.2%)
Splenomegaly 278 (54.4%) 5 (11.9%)
 Associated disorders and risk factors
Alcohol drinking (n = 324/30) 140 (43.2%) 4 (13.3%)
Chronic HBV infection only (n = 467/26) 207 (44.3%) 4 (15.4%)
Chronic HCV infection only (n = 467/26) 201 (43.0%) 3 (11.5%)
Chronic HBV/HCV infection (n = 467/26) 20 (4.3%) 0
Cirrhosis (n = 460/24) 454 (98.7%) 9 (37.5%)
Diabetes (n = 457/35) 90 (17.6%) 4 (11.4%)
Hypertension (n = 456/35) 102 (20.0%) 7 (20.0%)
 Unless otherwise indicated the values represent the number. Mean values are associated 
with the standard deviation (SD). The sex ratio was calculated as males:females. n = Total 
number of HCC patients/CCA patients with data available; ND = not determined. 
 Table 1.  Characteristics of the HCC and 
CCA patients
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patients as well as the clinical manifestations, risk factors, 
and associated disorders are given in  table 1 . 
 Of the HCC patients, a large majority (76.9%) were 
more than 50 years old. The distribution of the data was 
fairly symmetrical (i.e., skewness coefficient = –0.04). Of 
the 42 CCA patients, 81% were more than 50 years old 
( fig. 1 ).
 A large subset of the HCC patients was farmers (n = 
136; 33.6%), whereas a majority of CCA patients were 
housewives or unemployed (n = 14; 40%). Professions of 
the remaining HCC cases were, in decreasing order, ei-
ther housewives/unemployed (n = 98; 24.2%), public sec-
tor employees (n = 87; 21.5%), or private sector employ-
ees (n = 84; 20.7%). Regarding CCA cases, 10 (28.6%) 
were farmers, 7 (20%) were private sector employees, and 
4 (11.4%) were public sector employees. Following hos-
pitalization, the average length of the medical stay was 6.5 
and 5.9 days for HCC and CCA patients, respectively.
 As mentioned above, information was not always 
available for the entire series. As a consequence, we men-
tion the true numbers corresponding to each parameter, 
which is the total number of HCC or CCA cases with data 
recorded ( tables 1,  2 ).
 Interestingly, chronic HBV and HCV infections (i.e., 
HBsAg+ and anti-HCV+, respectively) showed similar 
rates in the HCC patient population, with 207 (44.3%) 
HBsAg+ cases and 201 (43%) anti-HCV+ cases. More-
over, 20 patients (4.3%) were infected both with HBV and 
HCV, while only 38 patients (8.1%) were neither infected 
with HBV nor with HCV.
 The mean age of HBsAg+ and anti-HCV– patients
(n = 207) was 52.1 ± 12.0 years, with an age range of 28–91 
years. The mean age of HBsAg– and anti-HCV+ patients 
(n = 201) was 63.9 ± 12.0 years, with a range of 36–89 
years. 
 Amongst HCC patients under 50 years, 99 (73.9%) 
were infected only with HBV (HBAgs+/anti-HCV–), 
whereas only 12 (9%) were infected with HCV alone 
(HBAgs–/anti-HCV+). Reciprocally, among the 229 
HCC cases aged over 60 years, 53 (23.1%) were infected 
with HBV, and 133 (58.1%) were infected with HCV.
 In CCA patients, serological results were available for 
only 26 patients. Among these, 19 (73.1%) were neither 
infected with HBV nor with HCV, 4 (15.4%) had chronic 
HBV infection, and 3 (11.5%) had chronic HCV infec-
tion.
 As shown in  table 2 , an elevation of serum aspartate 
aminotransferase and alanine aminotransferase was 
found, respectively, in 98 and 61% of the HCC cases and 
in 89.7 and 46.2% for the CCA cases. Total and direct 
bilirubin levels were increased in 84.8 and 88.6% of the 
HCC cases and in 89.5 and 97.4% of the CCA patients. 
γ-Glutamyl transpeptidase and alkaline phosphatase lev-
els were elevated for 82.3 and 73.2% of the HCC patients, 
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 Fig. 1. Age distribution of the 511 HCC ( a ) and 42 CCA ( b ) patients admitted to the Calmette Hospital between 2003 and 2015. 
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respectively, and for 90.6 and 93.1% of the CCA patients. 
Statistical analyses of biochemistry parameters were also 
performed (online suppl. table 1; for all online suppl. ma-
terial, see www.karger.com/doi/10.1159/000446398).
 The AFP level was documented for 366 HCC patients 
and 19 CCA patients, with the corresponding percentage 
of 63.1 and 5.3% values above 350 ng/ml. High AFP levels 
(>350 ng/ml) among HCC patients are associated signifi-
cantly with larger nodules (p = 0.05) and multifocal tumor 
(p = 0.03) when compared with low AFP expressers (<350 
ng/ml). Moreover, statistical analyses between a normal 
AFP level (<10 ng/ml) and an abnormal AFP level (>10 
ng/ml) in HCC patients indicate a significant association 
with the latter and chronic HCV infection (p = 0.05).
 Palliative treatment was the only option for 429 (84%) 
HCC patients; only 11 (2.1%) patients had a hepatectomy, 
10 (2.0%) patients were given oral chemotherapy with 
sorafenib, and 61 (11.9%) patients received tamoxifen. Of 
the CCA patients, 11 (26.2%) benefited from systemic 
chemotherapy (including GEMOX, FOLFOX, and FOL-
FIRI protocols), whereas 31 patients (73.8%) received 
palliative treatment only. Some of the most affluent pa-
tients decided, however, to benefit from surgical inter-
vention outside the country. They represent approxi-
mately 5–10% of the patients attending the Calmette Hos-
pital for liver tumor. 
 Clinicobiological Correlations 
 Age was an important feature structuring the series of 
patients with HCC. When considering the whole cohort 
in age quartiles ( fig. 2 a–e), significant differences related 
to age were found for HBsAg seroreactivity (p < 0.0001), 
sex ratio (p = 0.0014), nodule size (p = 0.0016), and alco-
hol consumption (p < 0.0001) that decrease with age, 
while the proportion of diabetes (p = 0.0005) and the an-
ti-HCV seroreactivity increase with age (p < 0.0001). Fi-
nally, the prevalence of abdominal pain (p = 0.0008) and 
jaundice decrease with age (p = 0.008).
 Table 2. Laboratory and radiologic findings of the HCC and CCA patients
Patient characteristics HCC patients CCA patients
Liver function test
AST (R <38) (n = 461/39), IU/l 196.8 (14 – 3,359) 124.6 (24 – 351)
ALT (R <50) (n = 461/39), IU/l 77.1 (10 – 415) 69.1 (13 – 102)
Total bilirubin (R <10) (n = 446/38), mg/l 61.6 (4 – 1,069) 183.5 (6 – 485)
Direct bilirubin (R <2.5) (n = 446/38), mg/l 36.4 (1 – 897) 123.3 (2 – 401)
GGT (R <66) (n = 344/32), IU/l 246.8 (12 – 3,412) 284.7 (11 – 1,213)
ALP (35< R <123) (n = 306/29), IU/l 278.6 (36 – 1,928) 431.2 (85 – 1,152)
Prothrombin time (70< R <100) (n = 420/28), % 60.4 (5 – 100) 71.8 (26 – 100)
Hemoglobin (130< R <170) (n = 366/16), g/l 101.7 (25 – 171) 92.3 (32 – 139)
Albumin (38< R <51) (n = 392/23), g/l 28.8 (15 – 52) 29.3 (20 – 48)
AFP (R <10) (n = 366/19)
<10 μg/l 53 (14.5%) 16 (84.2%)
10 – 100 μg/l 50 (13.7%) 2 (10.5%)
100 – 350 μg/l 32 (8.7%) 0
>350 μg/l 231 (63.1%) 1 (5.3%)
Imaging features
Nodule size (n = 345/13), mm 64.1 (10 – 185) 39.8 (22 – 72)
Multinodular type (n = 319/15) 212 (66.5%) 6 (40%)
Therapy (n = 511/42)
Palliative 429 (84%) 31 (73.8%)
Systemic/oral chemotherapy 71 (13.9%) 11 (26.2%)
Hepatectomy 11 (2.1%) 0
PEI/TOEC 0 0
Transplantation 0 0
Values represent mean (range) or number. n = Total number of HCC patients/CCA patients with data 
available; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase;
GGT = γ-glutamyl transpeptidase; PEI = percutaneous ethanol injection; R= reference values; TOEC = transarterial 
oil chemoembolization. 
D
ow
nl
oa
de
d 
by
: 
19
0.
23
8.
21
6.
16
9 
- 8
/2
6/
20
16
 1
2:
44
:0
8 
AM
 A Retrospective Study on Primary Liver 
Cancer in Cambodia 
 Oncology 2016;91:106–116 
DOI: 10.1159/000446398
111
 In addition, we conducted gender comparisons 
amongst HCC patients ( fig.  2 f–h). The results indicate 
that men develop tumors 3 years earlier than women 
(56.8 vs. 61.5 years; p < 0.0001), hepatomegaly prevalence 
was higher in men (48.8 vs. 32.4%; p = 0.001), while arte-
rial hypertension was more frequent among women (16.8 
vs. 36.7%; p < 0.0001). Regarding lifestyle risk factors, al-
cohol consumption and tobacco smoking were, as expect-
ed, significantly higher in men than in women (50.6 vs. 
17.9% and 48.9 vs. 5.6%; p < 0.0001 in both cases), where-
as anti-HCV seroreactivity was more frequent in the fe-
male group (38.1 vs. 55.4%; p = 0.0009). Symmetrically, 
HBsAg seropositivity was more prevalent among males 
(50 vs. 29.4%; p < 0.0001).
 We then compared the two monoinfected subsets of 
patients. The results show that the sex ratio was signifi-
cantly higher in the HBV+ group than in the HCV+ group 
(4.4 vs. 1.8; p < 0.0001), the patients were younger (52.1 
vs. 63.8 years; p < 0.0001), and alcohol consumption was 
more frequent in the HBV+ group (45.7 vs. 32.5%; p = 
0.04), whereas diabetes mellitus was less frequent (15.5 vs. 
25.6%; p = 0.02). Regarding biochemical features, serum 
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alkaline phosphatase and serum aspartate aminotransfer-
ase were significantly higher (302.8 vs. 218.7 and 213.5 vs. 
170.4 IU/l; p < 0.05 in both cases), and tumor nodules 
were bigger in the HBV+ group (67.5 vs. 59.3 mm; p = 
0.04) compared to the HCV+ group.
 Frequency and Spatial Distribution of HCC and CCA 
Patients 
 Among the HCC patient population, the highest num-
ber of cases originated from the Phnom Penh province
(n = 197; 38.6%) followed by the Kandal province (n = 59; 
11.5%) and the Kampong Cham province (n = 46; 9%). In 
the case of CCA, Phnom Penh (n = 13; 30.9%), Kampong 
Cham, and Kandal provinces (both n = 6; 14.3%) exhib-
ited the highest values (online suppl. fig. 1).
 Concerning the characteristics of HCC patients for 
each province, we noticed that Phnom Penh and Kandal 
provinces display similar features, such as an older age of 
patients (a mean of 60.8 and 59.4 years, respectively), a 
male:female sex ratio of 2.5 and 2.3, respectively, and a 
high proportion of diabetes mellitus (30.2 and 25.9%, re-
spectively). Conversely, patients from the Prey Veng and 
Takeo provinces, on the southern border, share compa-
rable features of young age at diagnosis (a mean of 52.8 
and 51.4 years, respectively), an elevated sex ratio (5.6 and 
14, respectively), a high proportion of alcohol consum-
ers (53 and 33%, respectively), and a high number of
HBsAg+ cases (61 and 86%, respectively). Concerning the 
spatial distribution of HBsAg+ and anti-HCV+ HCC pa-
tients, we observed a great disparity of distribution of the 
two types of hepatitis viruses between different Cambo-
dian provinces ( fig. 2 i, j,  3 ).
 In Phnom Penh, the proportion of patients infected 
with HBV was significantly lower than in other prov-
inces (39.8 vs. 50.5%, respectively, p = 0.03), whilst, in 
contrast, a significantly greater subset was infected with 
HCV (53.2 vs. 39.4%, respectively, p = 0.004). Similarly, 
Kampong Cham province displayed a strikingly differ-
ent proportion of patients infected either with HBV or 
with HCV (66.7 and 27.3%, respectively) with signifi-
cant differences in both subpopulations (p = 0.006 and 
p = 0.02, respectively). Finally, Takeo province showed 
the highest proportion of HBV+ patients (85.8%, p = 
0.004) and the lowest proportion of HCV+ patients 
(14.3%, p = 0.03).
 Discussion 
 This study aimed to characterize the forms and the eti-
ological factors of PLC in Cambodia through a retrospec-
tive analysis of the cohort treated in the Calmette Hospi-
tal from 2003 and 2015. It is also the first review on CCA 
patients in the country and provides relevant information 
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about epidemiological features of HCC and CCA among 
Cambodian people. 
 Interestingly, we found a similar rate of chronic infec-
tion with HBV (44.3%) and HCV (43%) among HCC pa-
tients. This observation was unexpected, since the overall 
contribution of HBV infection to PLC is more than twice 
higher than that of HCV infection worldwide, 53 and 
25%, respectively  [10] . 
 However, the infection rate found in our study cannot 
be extrapolated to the whole country, since the only avail-
able survey of PLC cases in Cambodia showed that the 
HBV and the HCV infection rate in HCC patients was 
46.4 and 21.5%, respectively  [4] . In this earlier study, the 
demographic and clinical characteristics of 281 cases di-
agnosed as primary HCC in the Khmer-Soviet Friendship 
Hospital (Phnom Penh, Cambodia) were described. The 
majority of the HCC patients were aged between 40 and 
69 (74.4%) and the male:female ratio was 3. These results 
are consistent with our data, since we found that 74.3% of 
the HCC cases were aged between 40 and 69 years, and 
the male:female ratio was 2.6. Furthermore, the mean age 
of the HCV+ HCC cases was 10 years higher than those 
with HBV+ (61.4 vs. 48 years old), which is quite similar 
to our results (63.9 vs. 52.1 years old). Moreover, the 
male:female ratio for HBV+ HCC patients was also simi-
lar to that found in our survey (4.4 and 4.5, respectively). 
Finally, the male:female ratio for HCV+ HCC cases was 
different to that found in our study (4 and 1.8, respec-
tively). These data could be explained by the small num-
ber of reported cases in the Khmer-Soviet Friendship 
Hospital (i.e., 45 patients) as described below.  
 In other Southeast Asian countries, a greater proportion 
of HBV infections compared to HCV infections is also 
consistently found among HCC patients. In some regions 
of Thailand, chronic HBV infection was identified in 49.6–
80% of HCC cases and chronic HCV infection in 10.1–
19.2%  [23–25] . In Vietnam, a review estimated the HCC-
HBV patients at 80–90% and the HCC-HCV patients at 
1–5%  [26] . In Malaysia, a recent study recorded HBV in 
57.6% of HCC patients and discovered HCV in only 2.4% 
of the same cohort  [27] . In the Asia-Pacific region, chron-
ic HBV infection accounts for 70–80% of the HCC cases, 
with the exception of Japan, Pakistan, and Mongolia where 
chronic HCV infection is predominantly found (68, 45, 
and 40% of the HCC cases, respectively)  [23, 28] .
 Many studies have already reported a large local varia-
tion in the prevalence of HBV and HCV infection, espe-
cially in Southeast Asia and Cambodia. For instance, the 
prevalence of HBsAg was reported to be 4.6% in Siem 
Reap province, 6.5% in Samlot City (Battambang prov-
ince), 8% in Takeo province, 8.8% in Pailin City (Pailin 
province), 9.4% in Banteay Meanchey province, and 
10.8% in Cambodian migrant workers from Thailand  [17, 
18, 29–31] . For HCV infection, the prevalence of anti-
HCV was 2.3% among Cambodian migrant workers from 
Thailand, 5.8% in Siem Reap province, 6.5% in Takeo 
province, 12.3% in Pailin City, and 17% in Samlot City 
 [15, 17, 18, 29] . These observations could explain the dif-
ference between the work of Narin  et al.  [4]  and our sur-
vey. This previous study was conducted in the Khmer-
Soviet Friendship Hospital where patients are usually 
coming from rural areas with lower socioeconomic sta-
tus, while in our study, patients are mostly capital city 
dwellers and belong to a higher social class. 
 The high number of incidences attributed to HCV in 
our work may appear surprising. However, it is known 
that there is still an increasing impact of HCV infection 
on the HCC burden in Asia. A recent study, conducted 
among Southeast Asian migrants in the US, revealed that 
both HBV and HCV are major causes of HCC in these 
populations  [32] . Moreover, a recent review has identi-
fied chronic hepatitis C as the true driving force for the 
increased incidence of HCC in Asia  [33] . 
 In Cambodia, unsafe injection practices, the absence 
of quality control and recycling, and the lack of proper 
sterilization of surgical instruments are known to be the 
main risk factors for HCV contamination  [34, 35] . There-
fore, inappropriate health-care practices plausibly repre-
sent the predominant source of HCV contamination in 
the country. Much of the data we recorded support these 
hypotheses. In this regard, it was clearly found that wom-
en with HCC show a higher rate of hepatitis C than men. 
This observation has been confirmed in a recent study on 
Asian migrants in the US  [32] , showing that female gen-
der is a risk factor for HCV-related HCC. According to 
Vong et al.  [35] , Cambodian women are more likely to 
receive therapeutic injections than men and are, there-
fore, more exposed to unsafe medical practices. More-
over, in an urban area such as Phnom Penh Province, 
where access to health care is easier than anywhere else in 
the country, patients were significantly more affected by 
HCV infection than HBV infection. Lastly, HCC cases 
with chronic HCV infection were not distributed homog-
enously as it is apparently the case with HBV-infected 
patients. These erratic contaminations could result from 
unsafe practices employed by local practitioners as re-
cently shown for the 2014 HIV infection outbreak in the 
village of Roka (Kandal province)  [36] . 
 The clinicopathological features of HBV- and HCV-
related HCC cases were drastically different. HBV-infect-
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ed patients displayed a strong male predominance, 
younger age, tobacco and alcohol dependency, and an ag-
gressive tumor presentation (liver functions, frequent 
hepatomegaly, nodule size) whereas HCV-infected cases 
displayed a lower male:female ratio, an older age, and, as 
expected, maturity-related comorbidities (diabetes mel-
litus and hypertension). Similar findings have already 
been reported from previous studies. The age difference 
at diagnosis is usually explained by the natural history of 
infection  [37–39] . Indeed, HBV contamination occurs 
mainly in the perinatal period or in childhood, whereas 
exposure to HCV usually occurs in adulthood. Moreover, 
the different mechanism in hepatocarcinogenesis be-
tween HBV-HCC and HCV-HCC could also explain 
these results. 
 A large majority of the PLCs recorded at the hospital 
was diagnosed as HCC (92.4%), while only few CCA cas-
es were reported (7.6%). Given the high prevalence of  O. 
viverrini infection (i.e., the main risk factor of CCA in the 
region) in some Cambodian provinces, the number of 
CCA patients was expected to be more important  [40] . In 
Thailand, the country with the populations presenting 
the highest rates of infestation  by O. viverrini , the propor-
tion of diagnosed CCA cases reaches 22.1% of all PLC in 
Bangkok, but ranges from 4% (Songkhla province in the 
south) to 82.1% (Khon Kaen province near the Laotian 
border in the north)  [5] . Several limitations of the survey 
such as the lack of histopathological examination could 
explain the low proportion of CCA diagnosed in the 
Calmette Hospital. 
 As mentioned above, our study has several limitations. 
First, missing data have already been reported as an im-
portant issue in Cambodian hospitals  [4] . This situation 
is primarily due to the high cost of medical investigations, 
which, in the absence of health insurance, have to be paid 
by the patients  [3] . Second, precise biological data on risk 
factors associated with these diseases were not obtained 
(i.e.,  O. viverrini infection, quantification of HBV DNA 
and HCV RNA, investigation of viral replication level). 
The third limitation of the present study stems from the 
fact that we studied liver cancer in a single Cambodian 
health-care facility, which is only partly representative of 
the overall HCC and CCA epidemiology of the country. 
Indeed, some patients are treated in private clinics and are 
not referred to a public hospital; others prefer to go to 
foreign countries (Vietnam, Thailand, and Singapore), 
while poor people cannot afford the cost of treatment and 
are either treated in a provincial hospital or not at all. An-
other limitation of our work is that the diagnosis was 
based on clinical features, tumor markers, and imaging 
tests. No histopathological examination was performed, 
and thus there might be misdiagnosis, albeit in a rather 
limited number of cases given the very evocative clinical 
context of the diseases reported (viral serology, AFP level, 
ultrasonography and computed tomography outcome). 
Finally, our survey is characterized by shortcomings in-
herent to cross-sectional observational studies and as 
such cannot compete with case-control or prospective 
studies. However, it has the merit to provide preliminary 
insights to conduct more informative epidemiological re-
search in the future.
 In conclusion, PLC represents a worrying public health 
issue in Cambodia. In our study, chronic HBV and HCV 
infections are contributing evenly to the bulk of HCC cas-
es (44.3 and 43%, respectively), while  O. viverrini infec-
tion is suspected to contribute to the CCA cases. The 
number of incidences attributed to HCV in the present 
series was surprisingly high (>40%) for a continental 
Southeast Asian country suggesting that the epidemiol-
ogy of HCC has changed locally during the last decades. 
This result should be taken seriously, because it is remi-
niscent of the current ongoing HCC catastrophe in Mon-
golia  [41] . Another observation that should stimulate the 
implementation of further investigations, preventive 
measures, and public information is the association of al-
cohol consumption and the early development of HCC in 
men. This observation is often overlooked in scientific 
literature and should prompt surveys investigating muta-
genic/carcinogenic properties of local alcoholic beverages 
 [42] . Our findings should now be used by local authorities 
in order to improve the surveillance of populations at risk 
to develop HCC or CCA as well as to prevent the diseases 
by avoidance both of transmission of the relevant infec-
tious agents and the consumption of carcinogenic com-
pounds. 
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Erratum
In the article by Mitchell et al., entitled ‘Validation of a preclinical model of diethylnitro-
samine-induced hepatic neoplasia in Yucatan miniature pigs’ [Oncology 2016;91:90–100, 
DOI: 10.1159/000446074], there is an error in the Materials and Methods section. Under 
the subheading of Anesthesia, the text reads: 
For all procedures, pigs were anesthetized via intramuscular injection with either tileta-
mine or zolazepam (6 mg/kg; Zoetis, Florham Park, N.J., USA) in a mixture of ketamine 
hydrochloride (15 mg/kg) and acepromazine maleate (0.15 mg/kg).
However, the text should read:
For all procedures, pigs were anesthetized via intramuscular injection with tiletamine/
zolazepam (6 mg/kg; Zoetis, Florham Park, N.J., USA) or a mixture of ketamine hydro-
chloride (15 mg/kg) and acepromazine maleate (0.15 mg/kg). 
D
ow
nl
oa
de
d 
by
: 
19
0.
23
8.
21
6.
16
9 
- 8
/2
6/
20
16
 1
2:
44
:0
8 
AM
